Our recently published clinical trial demonstrated the promising therapeutic responses in elderly AML patients or ineligible for IC treated with Aza combined with HAG (HHT, low-dose cytarabine, G-CSF) (23). The gene discussed is CSF3; the disease is acute myeloid leukemia.